Aytu BioPharma (NASDAQ:AYTU) Stock Price Up 0.8%

Aytu BioPharma, Inc. (NASDAQ:AYTU)’s share price rose 0.8% during mid-day trading on Tuesday . The stock traded as high as $3.09 and last traded at $3.08. Approximately 7,482 shares were traded during trading, a decline of 63% from the average daily volume of 20,044 shares. The stock had previously closed at $3.06.

Aytu BioPharma Stock Performance

The stock has a market cap of $16.93 million, a P/E ratio of -0.75 and a beta of -1.21. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.11 and a quick ratio of 0.91. The firm’s 50-day moving average price is $2.90 and its 200-day moving average price is $2.70.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $22.93 million for the quarter. Aytu BioPharma had a negative return on equity of 41.00% and a negative net margin of 18.27%.

Hedge Funds Weigh In On Aytu BioPharma

Large investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC bought a new position in Aytu BioPharma in the second quarter worth about $756,000. Renaissance Technologies LLC increased its holdings in shares of Aytu BioPharma by 22.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,140,782 shares of the company’s stock valued at $405,000 after acquiring an additional 393,262 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Aytu BioPharma by 190.3% during the fourth quarter. Millennium Management LLC now owns 1,189,958 shares of the company’s stock valued at $225,000 after acquiring an additional 780,116 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Aytu BioPharma during the first quarter valued at about $106,000. Finally, Vanguard Group Inc. increased its holdings in shares of Aytu BioPharma by 110.1% during the fourth quarter. Vanguard Group Inc. now owns 27,251 shares of the company’s stock valued at $77,000 after acquiring an additional 14,278 shares in the last quarter. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.